



<b>Office Action Summary</b>	<b>Application No.</b> 10/691,528	<b>Applicant(s)</b> WILHELM ET AL.	
	<b>Examiner</b> Matthew L. Fedowitz	<b>Art Unit</b> 1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 26 July 2002.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☐ Claim(s) \_\_\_\_ is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-17 is/are rejected.
- 7) ☒ Claim(s) 6 and 13 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |  |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>10/24/2003</u> . | 6) <input type="checkbox"/> Other: ____  |

***Objections***

- A. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The following title is suggested:  
“Novel Urokinase Inhibitors and Uses Thereof.”
- B. Claims 6 and 13 are objected to because the spelling of “5-fluoruracil” is incorrect. The correct spelling is “5-fluorouracil.” Claims 6 and 13 are also objected to because the claims as written state “and taxanes” or “and taxane,” respectively, thereby referring to taxane as a drug in itself. The term “taxane” in the pharmaceutical arts refers to a class of drugs called “taxanes.” Claims 5 and 13 should be written as “and a taxane.” Appropriate correction is required.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. § 103(a) that forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103(a) are summarized as follows:

- 1) Determining the scope and contents of the prior art.
- 2) Ascertaining the differences between the prior art and the claims at issue.
- 3) Resolving the level of ordinary skill in the pertinent art.
- 4) Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-17 are rejected under 35 U.S.C. § 103(a) as being unpatentable over PENTAPHARM Product Catalog 1998, Xing *et al.* Cancer Research 57, 3585-3593 (1997), DeVita *et al.* (Cancer Principles & Practice of Oncology, Fifth Edition. Lippincott Williams & Wilkins 1997) and Medenica *et al.* (US 5,736,129)

A. Claim 1 is directed to a method for inhibiting the growth and/or spreading of malignant tumors, metastases and/or lung foci by administering the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt in a pharmaceutically acceptable carrier. Claim 2 further limits claim 1 and is directed to defining the tumor as one that affects lymphatic tissue. Claim 3 further limits claim 2 and is directed to defining the lymphatic tissue as lymph nodes. Claim 4 further limits claim 3 by defining the lymph nodes as axillary lymph nodes and intraperitoneal lymph nodes. Claim 5 further limits claim 1 by including the administration of a cytotoxic substance. Claim 6 further limits claim 5 by defining the cytotoxic substance as being elected from the group consisting of cisplatin, carboplatin, doxorubicin, epirubicin, 5-fluoruracil and taxane. Claim 7 further limits claim 6 by defining the taxane as paclitaxel. Claims 8 and 9 further limit claim 1 by defining the malignant tumors as breast cancer tumors and where the composition is administered once daily to once weekly.

Claim 16 is directed to a method of treating a malignant tumor by removing the tumor and administering the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt in a pharmaceutically







Claim 15 is directed to a kit comprising separate containers where one contains the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt and the other contains radio labels and/or cytotoxic substances.

The teachings of Xing *et al.* are considered above. Xing *et al.* does not teach the use of the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt in a pharmaceutically acceptable carrier. Xing *et al.* also does not teach that the cytotoxic substance should be selected from a group consisting of cisplatin, carboplatin, doxorubicin, epirubicin, 5-fluoruracil and taxane; where the taxane is paclitaxel. Xing *et al.* also does not teach a kit comprising the claimed composition with and radio labels or cytotoxic substances

As relating to claims 10-15, the 1998 PENTAPHARM Product Catalog teaches the hydrochloride salt of N $\alpha$ (2,4,6-Triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl-piperazide. The catalog also describes the compound in the following manner: "Pefabloc® uPA is a low molecular weight synthetic inhibitor for urokinase." Moreover, it is well known in the pharmaceutical arts that a compound must be in the form of a weak acid in order for it to go into a pharmaceutical carrier solution.

Therefore, it would have been obvious to one having ordinary skill in this art at the time the invention was made and having the above cited references before him to obtain a pharmaceutical composition comprising the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt in a pharmaceutically acceptable carrier as well as an additional pharmacologically



active substance; where the pharmacologically active substance is selected from group of radio labels or cytotoxic substances; where the pharmacologically active substance is narrowed to a cytotoxic substance; where the cytotoxic substance is selected from the group consisting of cisplatin, carboplatin, doxorubicin, epirubicin, 5-FU and a taxane and where the taxane is paclitaxel. Moreover, it would have been obvious to one having ordinary skill in this art at the time the invention was made and having the above-cited references before him to obtain a kit containing the above-mentioned contents because of the complementary use of the compositions.

Xing *et al.* provides the motivation for a pharmaceutical composition or a kit comprising the L enantiomer of N $\alpha$ (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)phenylalanine-4-ethoxycarbonylpiperazide as itself or as a salt in a pharmaceutically acceptable carrier as well as an additional pharmacologically active substance. This is because Xing *et al.* specifically state that “the efficacy of currently available therapies for breast cancer is restricted by the disseminated nature of the disease, which is characterized by the progression of the majority of tumors to a phenotype that is resistant to both cytotoxic and hormonal therapies” and “therefore, the development of a complementary approach ... is required” (see pp. 3589-3590 first paragraph of discussion).

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew L. Fedowitz whose telephone number is (571) 272-3105. The examiner can normally be reached on 9am-5:30pm (EST) M-F.


Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

---

Matthew L. Fedowitz, Pharm.D., J.D.  
November 12, 2004



---

James O. Wilson  
Supervisory Patent Examiner  
Art Unit 1623